Table 6.
Recipient C1/x and donor KIR B haplotype in reduced intensity conditioning HCT
| Recipient C1/x | Recipient C2/C2 | |||||||
|---|---|---|---|---|---|---|---|---|
| Factor | n | HR | 95% CI | P | n | HR | 95% CI | P |
| Relapse | ||||||||
| Donor KIR haplotype | .037 * | .57* | ||||||
| AA | 302 | 1 | 32 | 1 | ||||
| BX | 631 | 0.78 | 0.62-0.98 | .037 | 97 | 0.82 | 0.40-1.65 | .57 |
| Donor KIR B centromeric regions | .042 * | .21* | ||||||
| AA | 428 | 1 | 54 | 1 | ||||
| AB | 416 | 0.80 | 0.62-1.02 | .071 | 66 | 0.80 | 0.40-1.62 | .54 |
| BB | 89 | 0.70 | 0.49-1.01 | .055 | 9 | 1.74 | 0.67-4.52 | .25 |
| DFS | ||||||||
| Donor KIR B haplotype | .040 * | .36* | ||||||
| AA | 302 | 1 | 32 | 1 | ||||
| BX | 629 | 0.85 | 0.72-0.99 | .040 | 97 | 0.80 | 0.50-1.29 | .36 |
| Donor KIR B centromeric regions | .66* | |||||||
| AA | 427 | 1 | 54 | 1 | ||||
| AB | 416 | 0.82 | 0.69-0.98 | .030 | 66 | 0.82 | 0.49-1.37 | .45 |
| BB | 88 | 0.74 | 0.54-1.01 | .060 | 9 | 1.17 | 0.54-2.56 | .68 |
| Overall survival | ||||||||
| Donor KIR haplotype | .87* | |||||||
| AA | 304 | 1 | 32 | 1 | ||||
| BX | 631 | 0.82 | 0.68-0.98 | .029 | 97 | 0.96 | 0.58-1.57 | .87 |
| Donor KIR B centromeric regions | .13* | .77* | ||||||
| AA | 430 | 1 | 54 | 1 | ||||
| AB | 416 | 0.85 | 0.71-1.01 | .067 | 66 | 0.84 | 0.49-1.43 | .52 |
| BB | 89 | 0.75 | 0.52-1.08 | .12 | 9 | 1.18 | 0.49-2.83 | .71 |
*
Overall P value.